Base de dados : MEDLINE
Pesquisa : C04.588.274.476.411.307.790.040 [Categoria DeCS]
Referências encontradas : 5113 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 512 ir para página                         

  1 / 5113 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28453692
[Au] Autor:Ott PA; Piha-Paul SA; Munster P; Pishvaian MJ; van Brummelen EMJ; Cohen RB; Gomez-Roca C; Ejadi S; Stein M; Chan E; Simonelli M; Morosky A; Saraf S; Emancipator K; Koshiji M; Bennouna J
[Ad] Endereço:Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, USA.
[Ti] Título:Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
[So] Source:Ann Oncol;28(5):1036-1041, 2017 05 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for patients with programmed death ligand 1 (PD-L1)-positive advanced solid tumors. We report results for the cohort of patients with advanced anal carcinoma. Patients and methods: Patients with PD-L1-positive tumors (≥1%) received intravenous pembrolizumab 10 mg/kg once every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter per Response Evaluation Criteria In Solid Tumors, version 1.1. Primary endpoints were safety and overall response rate per investigator review. Secondary endpoints included progression-free survival, overall survival, and response duration. Data cutoff date was 1 July 2015. Results: Of the 43 patients with advanced anal carcinoma evaluable for PD-L1 expression, 32 (74%) had PD-L1-positive tumors as assessed with the 22C3 prototype assay, of whom 25 were enrolled between April and September 2014. Sixteen patients (64%) experienced treatment-related adverse events; the most common ones were diarrhea and fatigue in four patients (16%) each and nausea in three patients (12%). There were no treatment-related deaths or discontinuations as of the data cutoff date. Among the 24 patients with squamous cell carcinoma histology, four had confirmed partial response, for an overall response rate of 17% [95% confidence interval (CI), 5%-37%) and 10 (42%) had confirmed stable disease, for a disease control rate of 58%. One additional patient with non-squamous histology had confirmed stable disease. Conclusion: In this population of patients with PD-L1-positive advanced squamous cell anal carcinoma, pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity. These data support further study of pembrolizumab for this patient population. ClinicalTrials.gov: NCT02054806.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Antineoplásicos Imunológicos/uso terapêutico
Neoplasias do Ânus/tratamento farmacológico
Carcinoma de Células Escamosas/tratamento farmacológico
Recidiva Local de Neoplasia/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Canal Anal/patologia
Anticorpos Monoclonais Humanizados/efeitos adversos
Antineoplásicos Imunológicos/efeitos adversos
Neoplasias do Ânus/mortalidade
Carcinoma de Células Escamosas/mortalidade
Intervalo Livre de Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Recidiva Local de Neoplasia/mortalidade
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents, Immunological); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdx029


  2 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463160
[Au] Autor:Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
[Ad] Endereço:University of Colorado Denver, Aurora, Colorado. Electronic address: Jeffrey.R.Olsen@ucdenver.edu.
[Ti] Título:Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):400-408, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer. This secondary analysis was performed to identify patient and treatment factors associated with acute and late gastrointestinal (GI) adverse events (AEs). METHODS AND MATERIALS: NRG Oncology RTOG 0529 treatment plans were reviewed to extract dose-volume data for tightly contoured small bowel, loosely contoured anterior pelvic contents (APC), and uninvolved colon outside the target volume (UC). Univariate logistic regression was performed to evaluate association between volumes of each structure receiving doses ≥5 to 60 Gy (V5-V60) in 5-Gy increments between patients with and without grade ≥2 acute and late GI AEs, and grade ≥3 acute GI AEs. Additional patient and treatment factors were evaluated in multivariate logistic regression (acute AEs) or Cox proportional hazards models (late AEs). RESULTS: Among 52 evaluable patients, grade ≥2 acute, grade ≥2 late, and grade ≥3 acute GI AEs were observed in 35, 17, and 10 patients, respectively. Trends (P<.05) toward statistically significant associations were observed between grade ≥2 acute GI AEs and small bowel dose (V20-V40), grade ≥2 late GI AEs and APC dose (V60), grade ≥3 acute GI AEs and APC dose (V5-V25), increasing age, tumor size >4 cm, and worse Zubrod performance status. Small bowel volumes of 186.0 cc, 155.0 cc, 41.0 cc, and 30.4 cc receiving doses greater than 25, 30, 35, and 40 Gy, respectively, correlated with increased risk of acute grade ≥2 GI AEs. CONCLUSIONS: Acute and late GI AEs from 5FU/MMC chemoradiation using DP-IMRT correlate with radiation dose to the small bowel and APC. Such associations will be incorporated in the dose-volume normal tissue constraint design for future NRG oncology anal cancer studies.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Neoplasias do Ânus/terapia
Carcinoma de Células Escamosas/terapia
Quimiorradioterapia/efeitos adversos
Intestino Delgado/efeitos da radiação
Radioterapia de Intensidade Modulada/efeitos adversos
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias do Ânus/diagnóstico por imagem
Neoplasias do Ânus/patologia
Carcinoma de Células Escamosas/patologia
Quimiorradioterapia/métodos
Colo/diagnóstico por imagem
Estudos de Viabilidade
Feminino
Fluoruracila/administração & dosagem
Fluoruracila/efeitos adversos
Seres Humanos
Intestino Delgado/diagnóstico por imagem
Masculino
Meia-Idade
Mitomicina/administração & dosagem
Mitomicina/efeitos adversos
Órgãos em Risco/diagnóstico por imagem
Órgãos em Risco/patologia
Órgãos em Risco/efeitos da radiação
Pelve/diagnóstico por imagem
Modelos de Riscos Proporcionais
Curva ROC
Dosagem Radioterapêutica
Radioterapia de Intensidade Modulada/métodos
Análise de Regressão
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antineoplastic Agents); 50SG953SK6 (Mitomycin); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  3 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27772624
[Au] Autor:Chin-Hong PV
[Ad] Endereço:Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA. Electronic address: peter.chin-hong@ucsf.edu.
[Ti] Título:Human Papillomavirus in Kidney Transplant Recipients.
[So] Source:Semin Nephrol;36(5):397-404, 2016 09.
[Is] ISSN:1558-4488
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human papillomavirus (HPV) is a common infection in kidney transplant recipients. HPV causes cervical, anal, vulvar, vaginal, penile and head and neck cancers. Kidney transplant recipients have a disproportionate burden of disease given prolonged immunosuppression. Given the long pre-invasive state of precancer lesions such as cervical intraepithelial neoplasia (CIN) and anal intraepithelial neoplasia (AIN) most HPV-cancers are preventable with screening and targeted treatment of disease. Pre-transplant vaccination of age-eligible kidney transplant recipients is otherwise ideal.
[Mh] Termos MeSH primário: Neoplasias do Ânus/virologia
Neoplasia Intraepitelial Cervical/virologia
Rejeição de Enxerto/prevenção & controle
Imunossupressores/efeitos adversos
Falência Renal Crônica/cirurgia
Transplante de Rim
Infecções por Papillomavirus/induzido quimicamente
Neoplasias do Colo do Útero/virologia
[Mh] Termos MeSH secundário: Neoplasias do Ânus/diagnóstico
Neoplasias do Ânus/prevenção & controle
Neoplasias do Ânus/terapia
Carcinoma in Situ/diagnóstico
Carcinoma in Situ/prevenção & controle
Carcinoma in Situ/terapia
Carcinoma in Situ/virologia
Neoplasia Intraepitelial Cervical/diagnóstico
Neoplasia Intraepitelial Cervical/prevenção & controle
Neoplasia Intraepitelial Cervical/terapia
Detecção Precoce de Câncer
Feminino
Seres Humanos
Masculino
Teste de Papanicolaou
Papillomaviridae
Infecções por Papillomavirus/diagnóstico
Infecções por Papillomavirus/prevenção & controle
Infecções por Papillomavirus/terapia
Vacinas contra Papillomavirus/uso terapêutico
Neoplasias do Colo do Útero/diagnóstico
Neoplasias do Colo do Útero/prevenção & controle
Neoplasias do Colo do Útero/terapia
Esfregaço Vaginal
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310363
[Au] Autor:Sun P; Ou H; Huang S; Wei L; Zhang S; Liu J; Geng S; Yang K
[Ad] Endereço:Department of Anorectal Surgery.
[Ti] Título:Perianal atypical leiomyoma: A case report.
[So] Source:Medicine (Baltimore);96(48):e8847, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Reports on perianal atypical leiomyoma, a perianal tumor, are rare. We confirmed a perianal atypical leiomyoma by its clinical presentation, magnetic resonance imaging findings, and immunohistochemistry. PATIENT CONCERNS: A 28-year-old female with a perianal mass found more than 4 years ago. The 5cm_4cm_4cm sized mass was located on the left side of the anus and vagina; The magnetic resonance imaging (MRI) scan revealed: A 4.1cm × 5.2cm × 4.9cm sized round mass was observed on the left side of the circumference. DIAGNOSES: Perianal atypical leiomyoma. INTERVENTIONS: anal peripheral mass resection was performed under lumbar anesthesia. OUTCOMES: The postoperative course was uneventful, healing, the patient was discharged. LESSONS: Perianal atypical leiomyomas are benign tumors, but with the clinically atypical leiomyoma, it is sometimes difficult to distinguish between potential malignant smooth muscle tumors,and there may be malignant changes. Surgery should ensure complete resection, and to avoid postoperative recurrence, there should be a regular follow-up.
[Mh] Termos MeSH primário: Neoplasias do Ânus/patologia
Neoplasias do Ânus/cirurgia
Leiomioma/patologia
Leiomioma/cirurgia
[Mh] Termos MeSH secundário: Adulto
Neoplasias do Ânus/diagnóstico
Feminino
Seres Humanos
Leiomioma/diagnóstico
Imagem por Ressonância Magnética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008847


  5 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190817
[Au] Autor:Serrano-Villar S; Hernández-Novoa B; de Benito A; Del Romero J; Ocampo A; Blanco JR; Masiá M; Sendagorta E; Sanz G; Moreno S; Pérez-Molina JA
[Ad] Endereço:Department of Infectious Diseases, Facultad de Medicina, Hospital Unversitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, Spain.
[Ti] Título:Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM.
[So] Source:PLoS One;12(11):e0188851, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Screening of anal cancer in HIV-infected MSM with anal cytology results in high rates of false positive results and elevated burden of high-resolution anoscopies. High-risk HPV up-regulates p16 and Ki67 expression in epithelial cells. We assessed the usefulness of P16/Ki-67 immunostaining cytology for the diagnosis of precancerous anal lesions. METHODOLOGY: Cross-sectional multicenter study. Concomitant anal liquid cytology with p16/Ki-67 immunostaining and HRA with biopsy of acetowhite lugol-negative lesions was performed in HIV-infected MSM. We compared the diagnostic performance of an abnormal anal cytology and p16/Ki-67 immunostaining relative to HRA-guided biopsy by logistic regression and comparison of ROC areas. RESULTS: We included 328 HIV-infected MSM. HSIL was histologically diagnosed in 72 subjects (25.1%), and 2 (0.6%) were diagnosed with anal cancer. An abnormal cytology showed a sensitivity of 95.6% and a specificity of 58.8% for the diagnosis of biopsy-proven HSIL. P16/Ki67 positivity was associated with the presence of biopsy-proven HSIL (P trend = 0.004) but with low sensitivity (41.2%) and specificity (71%). The combination of standard cytology with P16/Ki67 immunostaining did not increment the predictive value of standard cytology alone (AUC 0.685 vs. 0.673, respectively, P = 0.688). CONCLUSION: In HIV-infected MSM P16/Ki67 immunostaining does not improve the diagnostic accuracy of anal cytology, which shows a high sensitivity yet poor specificity. Other approaches aimed at improving the diagnostic accuracy of current techniques for the diagnostic of precancerous HSIL are warranted.
[Mh] Termos MeSH primário: Neoplasias do Ânus/diagnóstico
Inibidor p16 de Quinase Dependente de Ciclina/metabolismo
Infecções por HIV/complicações
Homossexualidade Masculina
Antígeno Ki-67/metabolismo
Lesões Pré-Cancerosas/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Neoplasias do Ânus/complicações
Seres Humanos
Masculino
Meia-Idade
Lesões Pré-Cancerosas/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclin-Dependent Kinase Inhibitor p16); 0 (Ki-67 Antigen); 0 (P16 protein, human)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188851


  6 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29206380
[Au] Autor:Sundling KE; Zhang R; Matkowskyj KA
[Ti] Título:Pathologic Features of Primary Colon, Rectal, and Anal Malignancies.
[So] Source:Cancer Treat Res;168:309-30, 2016.
[Is] ISSN:0927-3042
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the United States, colorectal cancer is the third most commonly diagnosed cancer in both men and women, as well as the third leading cause of cancer deaths (Colorectal cancer facts & figures 2014­2016, 2014 [2]). Worldwide, colorectal cancer is the fourth leading cause of death and causes almost 700,000 deaths each year (Cancer: fact sheet No. 297, 2015 [55]). This chapter discusses the clinical and pathologic features of the spectrum of epithelial, hematolymphoid, and mesenchymal malignant tumors of the colon, rectum, appendix, and anus.
[Mh] Termos MeSH primário: Neoplasias do Ânus/patologia
Neoplasias do Colo/patologia
Neoplasias Retais/patologia
[Mh] Termos MeSH secundário: Neoplasias do Ânus/genética
Neoplasias do Colo/genética
Tumores do Estroma Gastrointestinal/patologia
Seres Humanos
Linfoma/patologia
Instabilidade de Microssatélites
Tumores Neuroendócrinos/patologia
Neoplasias Retais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171221
[Lr] Data última revisão:
171221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  7 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173369
[Au] Autor:Wang S; Yin WB; Kong LY
[Ad] Endereço:Department of Anorectal Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
[Ti] Título:Anal Fistulas Due to Pseudomyxoma Anorectum.
[So] Source:Am J Med Sci;354(5):e9, 2017 Nov.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias do Ânus
Pseudomixoma Peritoneal
Fístula Retal
[Mh] Termos MeSH secundário: Neoplasias do Ânus/patologia
Neoplasias do Ânus/cirurgia
Seres Humanos
Masculino
Meia-Idade
Pseudomixoma Peritoneal/patologia
Pseudomixoma Peritoneal/cirurgia
Fístula Retal/patologia
Fístula Retal/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171206
[Lr] Data última revisão:
171206
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  8 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745699
[Au] Autor:Tsarkov PV; Efetov SK; Sidorova LV; Tulina IA
[Ad] Endereço:Sechenov First Moscow State Medical University, Department of colorectal and endoscopic surgery, Moscow, Russia.
[Ti] Título:[Sacral resection in surgical treatment of locally advanced primary and recurrent rectal and anal cancer: short-term outcomes].
[Ti] Título:Rezektsiia kresttsa pri khirurgicheskom lechenii mestno-rasprostranennogo pervichnogo i reditsivnogo raka priamoi kishki i anal'nogo kanala: neposredstvennye rezul'taty..
[So] Source:Khirurgiia (Mosk);(7):4-13, 2017.
[Is] ISSN:0023-1207
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To assess safety of rectum removal with distal sacral resection. MATERIAL AND METHODS: The short-term results of surgical treatment of primary and recurrent locally advanced rectal and anal cancer with sacral fixation have been analyzed. 32 patients underwent combined operations with sacral resection at the level of S2-S5. In 12 patients only one point of tumor fixation (F1) was revealed, 10 patients had two points of fixation (F2), three patients had three fixation points (F3) and in 7 cases the tumor was fixed to four points (F4) of fixation to different pelvic structures. RESULTS AND DISCUSSION: Mean intraoperative blood loss and surgery time was 551±81 ml and 320±20 min in cases of sacral fixation only that was significantly lower compared with F2 cases - 1278±551 ml and 433±45 min, F3 cases - 2200±600 ml and 620±88 min, F4 cases - 2157±512.5 ml and 519±52,3 min, respectively (Ñ€<0.05). Complications requiring surgical intervention occurred in 9% patients (n=3). Among 23 patients with intact bladder and ureters urinary disorders occurred in 42% (n=10). Resection margin was negative along posterior surface of the specimen in all cases. CONCLUSION: Advanced surgery with distal sacral resection is advisable for radical removal of locally advanced and recurrent rectal and anal canal cancer fixed to the sacrum with negative resection margin. These operations are feasible in specialized centers and should be performed by specially trained oncological or colorectal surgeon.
[Mh] Termos MeSH primário: Adenocarcinoma
Neoplasias do Ânus
Procedimentos Cirúrgicos do Sistema Digestório
Recidiva Local de Neoplasia
Complicações Pós-Operatórias
Neoplasias Retais
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Adenocarcinoma/cirurgia
Neoplasias do Ânus/patologia
Neoplasias do Ânus/cirurgia
Procedimentos Cirúrgicos do Sistema Digestório/efeitos adversos
Procedimentos Cirúrgicos do Sistema Digestório/métodos
Estudos de Viabilidade
Feminino
Seres Humanos
Masculino
Margens de Excisão
Meia-Idade
Invasividade Neoplásica
Recidiva Local de Neoplasia/patologia
Recidiva Local de Neoplasia/cirurgia
Estadiamento de Neoplasias
Duração da Cirurgia
Avaliação de Processos e Resultados (Cuidados de Saúde)
Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/epidemiologia
Neoplasias Retais/patologia
Neoplasias Retais/cirurgia
Federação Russa
Sacro/patologia
Sacro/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171130
[Lr] Data última revisão:
171130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.17116/hirurgia201774-13


  9 / 5113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29069019
[Au] Autor:Muradbegovic M; St-Amour P; Martin D; Petermann D; Benabidallah S; Di Mare L
[Ad] Endereço:aDepartment of General and Visceral Surgery, EHC Hospital, Morges b Department of Visceral Surgery, University Hospital CHUV, Lausanne cUnilabs, Department of Pathology, Lausanne, Switzerland.
[Ti] Título:End-colostomy diverticulitis with parastomal phlegmon: A case report.
[So] Source:Medicine (Baltimore);96(43):e8358, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Acute colonic diverticulitis is a well-known surgical emergency, which occurs in about 10 percent of patients known for diverticulosis. PATIENT CONCERNS: The case of a 77-year-old woman is reported, with past history of abdominoperineal resection with end-colostomy for low rectal adenocarcinoma, and who developed an acute colonic diverticulitis in a subcutaneous portion of colostomy with parastomal phlegmon. DIAGNOSES: Initial computed tomography imaging demonstrated a significant submucosal parietal edema with local fat tissues infiltration in regard of 3 diverticula. INTERVENTIONS: A two-step treatment was decided: first a nonoperative treatment was initiated with 2 weeks antibiotics administration, followed by, 6 weeks after, a segmental resection of the terminal portion of the colon with redo of a new colostomy by direct open approach. OUTCOMES: Patient was discharged on the second postoperative day without complications. Follow-up at 2 weeks revealed centimetric dehiscence of the stoma, which was managed conservatively until sixth postoperative week by stomatherapists. LESSONS SUBSECTIONS: Treatment of acute diverticulitis with parastomal phlegmon in a patient with end-colostomy could primary be nonoperative. Delayed surgical treatment with segmental colonic resection was proposed to avoid recurrence and potential associated complications.
[Mh] Termos MeSH primário: Celulite (Flegmão)/etiologia
Colostomia/efeitos adversos
Doença Diverticular do Colo/etiologia
Complicações Pós-Operatórias/etiologia
Estomas Cirúrgicos/efeitos adversos
[Mh] Termos MeSH secundário: Neoplasias Abdominais/cirurgia
Idoso
Neoplasias do Ânus/cirurgia
Feminino
Seres Humanos
Períneo/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171123
[Lr] Data última revisão:
171123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171026
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008358


  10 / 5113 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28985845
[Au] Autor:Funder JA; Tolstrup R; Jepsen BN; Iversen LH
[Ad] Endereço:Department of Surgery, Colorectal Section, Aarhus University Hospital, Aarhus, Denmark. Electronic address: funder@clin.au.dk.
[Ti] Título:Postoperative paralytic ileus remains a problem following surgery for advanced pelvic cancers.
[So] Source:J Surg Res;218:167-173, 2017 Oct.
[Is] ISSN:1095-8673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Paralytic postoperative ileus (POI) is associated with increased morbidity and mortality after abdominal surgery. Despite increased awareness and implementation of various measures, POI remains a problem, perhaps moreso for those patients undergoing extensive oncological surgical treatment. The aim of this study was to describe the extent of POI after advanced cancer surgery in the era of contemporary treatment modalities of POI. METHODS: A retrospective analysis of all patients who underwent either abdominoperineal excision with transpelvic vertical rectus abdominal musculocutaneous (VRAM)-flap after anal cancer or pelvic exenteration at single institution from January 2012 to November 2013 was carried out. Patients were identified from operative codes, and data were retrieved from patient records. RESULTS: Eighty-nine patients were included in the study, 21 abdominoperineal excision and 68 pelvic exenteration procedures. Median nasogastric tube duration was 4 days (range: 0-44). Median time to first flatus was 1 day (range 0-15). Median time to defecation was 3 days (range 0-16 days). Twenty-three patients (28%) experienced prolonged ileus. There was a significant longer time to first defecation for patients who received a VRAM flap (P = 0.046). There was also a significant association between longer operative times and first flatus (P = 0.007). CONCLUSIONS: This retrospective study reveals that POI remains as a significant clinical problem in patients undergoing advanced pelvic cancer surgery, despite the increased awareness and implementation of enhanced recovery protocols. New regimens for better prophylaxis are needed, and further research on POI treatment is important.
[Mh] Termos MeSH primário: Neoplasias do Ânus/cirurgia
Pseudo-Obstrução Intestinal/etiologia
Exenteração Pélvica/efeitos adversos
Complicações Pós-Operatórias/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171008
[St] Status:MEDLINE



página 1 de 512 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde